Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
A phase 1/2 trial of Gotistobart, Pembrolizumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by OncoC4, Inc., active and no longer recruiting.
Overview
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC is a phase 1/2 interventional study registered as NCT04140526 by OncoC4, Inc., with 733 participants planned, started 2020-09-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: ONC-392, Pembrolizumab, Docetaxel. Conditions listed: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Shares OncoC4, Gotistobart, Non-small-cell lung cancer.
- TrialONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Shares OncoC4, Gotistobart, Pembrolizumab.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Colorectal cancer.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialGM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Colorectal cancer.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Docetaxel, Melanoma, Small-cell lung cancer, Colorectal cancer.